The injectable drug delivery market would grow at a CAGR of 9.05% over the predicted time frame. The market is expected to increase in value from US$ 611.84 Bn in 2022 to US$ 1,223.6 Bn in 2030.
The on injectable
drug delivery Market, which provides a business strategy, research &
development activities, concise outline of the market valuation, valuable
insights pertaining to market share, size, supply chain analysis, competitive
landscape and regional proliferation of this industry.
Download
Free Sample@ https://www.precedenceresearch.com/sample/1760
Report Scope of the Infant Injectable Drug Delivery Market
| Report Coverage | Details |
| Market Size by 2030 | USD 1,223.6 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 9.05% |
| Largest Market | North America |
| Fastest Growing Market | Europe |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Type, Formulation Packaging, Therapeutic Application, Usage Pattern, Site of Administration, Distribution Channel, Facility of Use, Geography |
A recent
report provides crucial insights along with application based and forecast
information in the Global Injectable drug delivery Market. The report provides
a comprehensive analysis of key factors that are expected to drive the growth
of this market. This study also provides a detailed overview of the
opportunities along with the current trends observed in the Injectable drug
delivery market.
A
quantitative analysis of the industry is compiled for a period of 10 years in
order to assist players to grow in the market. Insights on specific revenue
figures generated are also given in the report, along with projected revenue at
the end of the forecast period.
Companies
and Manufacturers Covered
The study
covers key players operating in the market along with prime schemes and
strategies implemented by each player to hold high positions in the industry.
Such a tough vendor landscape provides a competitive outlook of the industry,
consequently existing as a key insight. These insights were thoroughly analysed
and prime business strategies and products that offer high revenue generation
capacities were identified. Key players of the global Injectable drug delivery
market are included as given below:
Injectable drug delivery Market Key Players
- Becton
- Dickinson and Company
- Pfizer Inc.
- Teva Pharmaceuticals Industries Ltd.
- Eli Lilly and Company
- Baxter International, Inc.
- Sandoz
- Terumo
- Schott AG
- Gerresheimer
- Ypsomed
- Bespak
- B. Braun Melsungen
Market Segments
- Devices
- Conventional Injectables
- Pre-Filled Syringes
- Auto-Injectors
- Pen-Injectors
- Formulations
By Formulation Packaging
- Ampules
- Vials
- Cartridges
- Bottles
By Therapeutic Application
- Auto-immune diseases
- Hormonal Disorders
- Orphan Diseases
- Oncology
- Others
By Usage Pattern
- Curative Care
- Immunization
- Other
By Site of Administration
- Skin
- Circulatory/Musculoskeletal
- Organs
- Central Nervous System
By Distribution Channel
- Hospitals & Clinics
- Retail Pharmacy Stores
- Others
By Facility of Use
- Hospitals & Clinics
- Home Care Settings
- Other
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
Report Objectives
- To define, describe, and forecast the global injectable
drug delivery market based on product, and region
- To provide detailed information regarding the major
factors influencing the growth of the market (drivers, opportunities, and
industry-specific challenges)
- To strategically analyze micromarkets1 with respect to
individual growth trends, future prospects, and contributions to the total
market
- To analyze opportunities in the market for stakeholders
and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to
four main regions—North America,
Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively
analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as
acquisitions, expansions, new product launches, and partnerships in the injectable
drug delivery market
Table of Content
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Injectable Drugs Delivery Market, By Type
7.1. Injectable Drugs Delivery Market, by Type, 2022-2030
7.1.1. Devices
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Formulations
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Injectable Drugs Delivery Market, By Formulation Packaging
8.1. Injectable Drugs Delivery Market, by Formulation Packaging, 2022-2030
8.1.1. Ampules
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Vials
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Cartridges
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.3. Bottles
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Injectable Drugs Delivery Market, By Therapeutic Application
9.1. Injectable Drugs Delivery Market, by Therapeutic Application, 2022-2030
9.1.1. Auto-immune diseases
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Hormonal Disorders
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Orphan Diseases
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Oncology
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Other Therapeutic Applications
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Injectable Drugs Delivery Market, By Usage Pattern
10.1. Injectable Drugs Delivery Market, by Usage Pattern, 2022-2030
10.1.1. Curative Care
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Immunization
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Other Usage Pattern
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Injectable Drugs Delivery Market, By Site of Administration
11.1. Injectable Drugs Delivery Market, by Site of Administration, 2022-2030
11.1.1. Skin
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Circulatory/Musculoskeletal
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Organs
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Central Nervous System
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Injectable Drugs Delivery Market, By Distribution Channel
12.1. Injectable Drugs Delivery Market, by Distribution Channel, 2022-2030
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Retail Pharmacy Stores
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Injectable Drugs Delivery Market, By Facility of Use
13.1. Injectable Drugs Delivery Market, by Facility of Use, 2022-2030
13.1.1. Hospitals & Clinics
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Home Care Settings
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.2. Other Facilities of Use
13.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Injectable Drugs Delivery Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.1.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.1.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.1.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.1.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.1.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.8.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.1.8.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.1.8.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.1.8.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.1.8.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.1.8.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.1.9.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.1.9.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.1.9.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.2.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.2.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.2.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.2.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.2.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.2.8.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.2.8.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.2.8.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.2.8.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.9.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.2.9.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.2.9.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.2.9.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.2.9.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.2.9.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.10.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.2.10.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.2.10.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.2.10.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.2.10.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.2.10.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Type (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.2.11.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.2.11.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.2.11.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.2.11.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.3.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.3.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.3.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.3.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.3.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.8.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.3.8.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.3.8.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.3.8.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.3.8.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.3.8.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.9.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.3.9.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.3.9.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.3.9.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.3.9.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.3.9.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.3.10.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.3.10.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.3.10.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Type (2017-2030)
14.3.11.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.3.11.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.3.11.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.3.11.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.3.11.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.3.11.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.4.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.4.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.4.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.4.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.4.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.8.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.4.8.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.4.8.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.4.8.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.4.8.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.4.8.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.9.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.4.9.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.4.9.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.4.9.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.4.9.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.4.9.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.4.10.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.4.10.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.4.10.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Type (2017-2030)
14.4.11.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.4.11.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.4.11.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.4.11.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.4.11.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.4.11.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.5.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.5.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.5.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.5.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.5.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.8.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.5.8.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.5.8.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.5.8.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.5.8.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.5.8.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Type (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Formulation Packaging (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Therapeutic Application (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Usage Pattern (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Site of Administration (2017-2030)
14.5.9.6. Market Revenue and Forecast, by Facility of Use (2017-2030)
14.5.9.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 15. Company Profiles
15.1. Becton
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Dickinson and Company
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Pfizer Inc.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Teva Pharmaceuticals Industries Ltd.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Eli Lilly and Company
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Baxter International, Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Sandoz
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Terumo
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Schott AG
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Gerresheimer
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments